<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01437215</url>
  </required_header>
  <id_info>
    <org_study_id>CP-0002</org_study_id>
    <nct_id>NCT01437215</nct_id>
  </id_info>
  <brief_title>Pilot Study of the Endologix Fenestrated Stent Graft System</brief_title>
  <official_title>Prospective, Multicenter, Single Arm Feasibility and Initial Safety Study of the Endologix Fenestrated Stent Graft System for the Endovascular Repair of Juxtarenal/Pararenal (JAA/PAA) Aneurysms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Endologix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Endologix</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the Endologix fenestrated stent graft&#xD;
      system is safe and feasible in the endovascular repair of juxtarenal or pararenal aortic&#xD;
      aneurysm.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2, 2010</start_date>
  <completion_date type="Actual">July 28, 2016</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety - Number of Major Adverse Events (MAEs)</measure>
    <time_frame>30 Days</time_frame>
    <description>Major Adverse Events = all cause death; bowel ischemia; myocardial infarction; paraplegia; renal failure; respiratory complications of stroke; blood loss &gt;1000cc</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility- Number of subjects with procedural success (stent graft patency) and absence of type I/III endoleaks or migration</measure>
    <time_frame>30 Days</time_frame>
    <description>Procedural Success with aortic/fenestrated and renal stent graft patency and absence of Type I/III endoleak or migration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety - Number of Major Adverse Events (MAEs)</measure>
    <time_frame>&gt;30 Days to 5 Years</time_frame>
    <description>Major Adverse Events = all cause death; bowel ischemia; myocardial infarction; paraplegia; renal failure; respiratory complications of stroke; blood loss &gt;1000cc</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Procedurally to 5 Years</time_frame>
    <description>All adverse events, whether serious or non-serious</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distal Blood Flow</measure>
    <time_frame>Discharge to 5 Years</time_frame>
    <description>Ankle-brachial index measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Dysfunction</measure>
    <time_frame>Discharge to 5 Years</time_frame>
    <description>eGFR reduction &gt;30% from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Performance</measure>
    <time_frame>30 Days to 5 Years</time_frame>
    <description>Aortic, fenestrated, and renal stent graft integrity and patency; migration; endoleak; and aneurysm sac morphology</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Juxtarenal Aortic Aneurysm</condition>
  <condition>Pararenal Aortic Aneurysm</condition>
  <arm_group>
    <arm_group_label>Fenestrated Endografting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ventana Fenestrated Stent Graft System</intervention_name>
    <description>Endovascular repair of juxtarenal or pararenal aortic aneurysm</description>
    <arm_group_label>Fenestrated Endografting</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent understood and signed and pt agrees to all follow-up visits;&#xD;
&#xD;
          -  Abdominal aortic aneurysm with diameter ≥5cm or ≥4cm which has increased by 0.5cm or&#xD;
             more in the past six months&#xD;
&#xD;
          -  Adequate iliac/femoral access compatible with the required delivery systems&#xD;
&#xD;
          -  Non-aneurysmal infrarenal aortic neck &lt;15mm in length&#xD;
&#xD;
          -  Most caudal renal artery to aortoiliac bifurcation length at least 70mm&#xD;
&#xD;
          -  Proximal non-aneurysmal aortic neck below the SMA with: diameter 18 to 34 mm; length&#xD;
             at least 15 mm; angle (clock face) &lt;60° to the aneurysm sac;&#xD;
&#xD;
          -  Angle &lt;60° (clock face) between the SMA and celiac artery&#xD;
&#xD;
          -  Renal arteries both distal to the SMA by 0-35mm, within 30mm of each other axially,&#xD;
             with 4 to 8mm lumen diameter, and with clockface angle of 90° to 210° to each other&#xD;
&#xD;
          -  Iliac anatomy suitable for commercial bifurcated stent graft;&#xD;
&#xD;
          -  Minimum 3cm overlap achievable between fenestrated and bifurcated stent grafts&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Life expectancy &lt;1 year as judged by the investigator;&#xD;
&#xD;
          -  Psychiatric or other condition that may interfere with the study;&#xD;
&#xD;
          -  Participating in the enrollment or 30-day follow-up phase of another clinical study;&#xD;
&#xD;
          -  Known allergy to any device component;&#xD;
&#xD;
          -  Coagulopathy or uncontrolled bleeding disorder;&#xD;
&#xD;
          -  Contraindication to contrast media or anticoagulants;&#xD;
&#xD;
          -  Ruptured, leaking, dissecting, or mycotic aneurysm;&#xD;
&#xD;
          -  Serum creatinine (S-Cr) level &gt;2.0 mg/dL;&#xD;
&#xD;
          -  Traumatic vascular injury;&#xD;
&#xD;
          -  Active systemic or localized groin infection;&#xD;
&#xD;
          -  Connective tissue disease (e.g., Marfan's Syndrome);&#xD;
&#xD;
          -  Recent (within prior three months) cerebrovascular accident or myocardial infarction;&#xD;
&#xD;
          -  Prior renal transplant;&#xD;
&#xD;
          -  Length of either renal artery to be stented &lt;13mm;&#xD;
&#xD;
          -  Significant occlusive disease or calcification of either renal artery;&#xD;
&#xD;
          -  An essential accessory renal artery;&#xD;
&#xD;
          -  Indispensable inferior mesenteric artery;&#xD;
&#xD;
          -  Untreated aneurysmal disease of the descending thoracic aorta;&#xD;
&#xD;
          -  Clinically significant mural thrombus circumferentially in the suprarenal segment;&#xD;
&#xD;
          -  Prior iliac artery stent implanted that may interfere with delivery system&#xD;
             introduction;&#xD;
&#xD;
          -  Unsuitable vascular anatomy&#xD;
&#xD;
          -  Pregnancy (female patient of childbearing potential only)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pontificia Universidad Católica de Chile</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 17, 2011</study_first_submitted>
  <study_first_submitted_qc>September 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2011</study_first_posted>
  <last_update_submitted>September 6, 2019</last_update_submitted>
  <last_update_submitted_qc>September 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aneurysm</keyword>
  <keyword>renal stent</keyword>
  <keyword>juxtarenal</keyword>
  <keyword>pararenal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

